Jazz Pharmaceuticals plc is a dynamic specialty biopharmaceutical company that identifies, develops and commercializes innovative products to address unmet medical needs in focused therapeutic areas, always keeping in mind our mission to improve patients' lives. Living our core values of integrity, passion, collaboration, innovation and the pursuit of excellence is the key to our success.
MISSION & VALUES
Our mission is to improve patients' lives by identifying, developing and commercializing important specialty pharmaceutical products to address unmet patient needs. We address serious diseases, always with the goal of improving patient care. Keeping patients at the forefront of our mind inspires us to bring innovative and valuable resources to all aspects of our business for the ultimate benefit of the patients in need.
Our core values define our corporate practices and demonstrate our commitment to improving patients' lives.
We value honesty and compliance with all of the laws, rules, regulations and corporate policies that apply to our business, and we expect the same total commitment from our employees, consultants, business partners and service providers. We view our uncompromising commitment to honesty and compliance as a core value - one that we look for in all of our employees.
Like the talented musicians who inspired our company name, we believe that the whole is much greater than the sum of its parts. Jazz musicians are known for working together to create new and exciting riffs or new variations on familiar themes. Similarly, the hallmark of our collaborative spirit is our ability to work together in creative teams to accomplish not only research and development goals, but also commercial and corporate objectives. Our value of and respect for one another support our collaboration on projects to help patients, patient advocates and our community.
Our passion is our unwavering commitment to improving patient care. The intensity we devote to our efforts and our focus on the efficient development of products to address unmet patient needs are clear evidence of our passion.
Innovation is essential to help patients and health care providers address unmet medical needs. Striving to provide new benefits for unmet patient needs requires us to look for novel solutions, particularly where others have been discouraged by the difficulty of the problem or the small size of the patient population.
PURSUIT OF EXCELLENCE
In all that we do - our passion and collaboration, our integrity and our caring for patients - we demonstrate our pursuit of excellence. We will always strive to take it to the next level.
WHAT'S IN A NAME?
The name "Jazz Pharmaceuticals" was inspired by the talented jazz musicians who come together - each a musical specialist with an individual style - to make music in concert that is greater than the sum of its parts. Jazz musicians are known for working together to create new and exciting riffs or new variations on familiar themes. Jazz music showcases the coexistence of improvisation and structure.
At Jazz Pharmaceuticals, we believe that each member of our team makes integral contributions working toward a common goal to improve patients' lives. The hallmark of our collaborative spirit is our ability to work together in creative teams to accomplish not only research and development goals, but also commercial and corporate objectives.
At Jazz Pharmaceuticals, our mission is to improve patients' lives by identifying, developing and commercializing products including: XYREM, ERWINAZE, PRIALT, FAZACLO LD and HD and LUVOX CR. The product information on XYREM, ERWINAZE, PRIALT, FAZACLO LD and HD and LUVOX CR is intended only for residents of the United States. Click on the logos below to view complete prescribing information, including boxed warnings.
In addition to these products marketed in the U.S., EUSA Pharma, an international division of Jazz Pharmaceuticals, markets products outside of the U.S. in more than 80 countries. For more information please visit: www.EUSAPharma.com.
To report an adverse event or a product complaint, or to request information about our products, please click here.
RESEARCH & DEVELOPMENT
Jazz Pharmaceuticals has an unwavering commitment to improving care for patients with serious medical conditions through innovative treatments. We are working to expand our current portfolio of commercial products through targeted investments in post-discovery research and development. We are working closely with healthcare professionals and patient advocates to identify significant treatment gaps where Jazz Pharmaceuticals' approach to patient care may be able to help solve problems in a unique way that will make a substantive difference for patients.
Our long-term vision includes building a development pipeline that could offer potential new treatment options for patients. Our current research and development efforts include programs to improve the current products in our oncology and psychiatry franchises, as well as other development opportunities that support our mission to improve patient's lives.
- IV formulation in development
- Exploring additional labeling opportunities
- Anti-CD25 monoclonal antibody
- Treatment of steroid-refractory acute graft vs. host disease
- EU Phase III study underway
- Pegylated recombinant erwinia asparaginase
- E. Coli asparaginase hypersensitivity
- Currently in Phase I development in EU
- Oral dosing formulation, for which an NDA has been submitted to
- Additional formulations to provide potential new dosing options to patients and physicians
- Once daily formulation undergoing evaluation
|CORPORATE HEADQUARTERS || |
| Fourth Floor, Connaught House, |
One Burlington Road, Dublin 4,
| || |
|U.S. LOCATIONS || |
3180 Porter Drive
Palo Alto, CA 94304
1818 Market Street, Suite 2350
Philadelphia, PA 19103
One Summit Square
1717 Langhorne-Newtown Road
Langhorne, PA 19047
|INTERNATIONAL DIVISION |
EUSA Pharma International Headquarters
Oxford UK office
The Magdalen Centre
Oxford Science Park
Oxford, OX4 4GA
|Firm ||Analyst |
|Bank of America Merrill Lynch ||Gregg Gilbert |
|Barclays Capital ||Douglas Tsao |
|Brean Murray Carret & Co. ||Gene Mack |
|Cantor Fitzgerald ||Irina Rivkind |
|Citi ||Jonathan Eckard, Ph.D. |
|Cowen & Co. ||Ken Cacciatore |
|Discern ||Patricia Bank |
|Guggenheim ||Louise Chen |
|Jefferies & Company ||Corey Davis, Ph.D. |
|Lazard Capital Markets ||William Tanner, Ph.D. |
|Leerink Swann ||Michael Schmidt, Ph.D. |
|Oppenheimer ||Christopher Holterhoff |
|Piper Jaffray ||David Amsellem |
|UBS ||Ami Fadia |
|Wallach Beth Capital, LLC ||Difei Yang, Ph.D. |